Interferon-α salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation

Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia

(2016) P Tsirigotis et al.   BONE MARROW TRANSPLANTATION

Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT

(2016) P Tsirigotis et al.   BONE MARROW TRANSPLANTATION

Successful Treatment of Relapsed Acute Myeloid Leukemia Without Chemotherapy

(2016) Xiaowen Tang et al.   JOURNAL OF CLINICAL ONCOLOGY

Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation

(2015) Xiao-Dong Mo et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell tra

(2015) Xiao-Dong Mo et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia

(2014) Yi-Bin Chen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen–Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study

(2014) Inpyo Choi et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification

(2014) Y. Wang et al.   BLOOD

Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome

(2014) X-D Mo et al.   BONE MARROW TRANSPLANTATION

Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity

(2013) Xiao-su Zhao et al.   ANNALS OF HEMATOLOGY

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

(2013) C. R. Y. Cruz et al.   BLOOD

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

(2013) H.-H. Zhu et al.   BLOOD

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

(2013) T Schroeder et al.   LEUKEMIA

Interferon α may be back on track to treat acute myeloid leukemia

(2013) Evelien L.J.M. Smits et al.   OncoImmunology

Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation

(2012) C.-H. Yan et al.   BLOOD

A disease risk index for patients undergoing allogeneic stem cell transplantation

(2012) P. Armand et al.   BLOOD

Diagnosis and management of acute graft-versus-host disease

(2012) Fiona L. Dignan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Diagnosis and management of chronic graft-versus-host disease

(2012) Fiona L. Dignan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation

(2012) F Baron et al.   LEUKEMIA

Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation

(2011) Xiao-Su Zhao et al.   ANNALS OF HEMATOLOGY

Wilms’ tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT

(2011) X-S Zhao et al.   BONE MARROW TRANSPLANTATION

Interferon-α in acute myeloid leukemia: an old drug revisited

(2011) S Anguille et al.   LEUKEMIA

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

(2011) U Platzbecker et al.   LEUKEMIA

Treatment of Acute Leukemia with Unmanipulated HLA-Mismatched/Haploidentical Blood and Bone Marrow Transplantation

(2009) Xiao-Jun Huang et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Partially Matched Related Donor Transplantation Can Achieve Outcomes Comparable with Unrelated Donor Transplantation for Patients with Hematologic Malignancies

(2009) H. Xiao-Jun et al.   CLINICAL CANCER RESEARCH

Successful cell-mediated cytokine-activated immunotherapy for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation

(2008) Benjamin Gesundheit et al.   AMERICAN JOURNAL OF HEMATOLOGY